Triple immunotherapy attack shows promise for tough skin cancer
NCT ID NCT06056895
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main goal is to see if the tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV MERKEL CELL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Blood markers could spot hidden skin cancer return
- Cancer-Killing virus shows promise in early trial for advanced tumors
- Immune cell therapy shows promise for tough cancers
- New database aims to crack the code on three rare skin cancers
- New scan could spot hidden tumors more accurately